GlassScriptPhysician profile
Jonben D Svoboda
NPI 1831198993
$141,568.31
in general payments reported to CMS, 2019-2025
38 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $32K · 2021: $36K · 2022: $16K · 2023: $843 · 2024: $924 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $90,289.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $37,099.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $9,865.77 | 2019-2021 | |
| Abbott Laboratories | $720.74 | 2019-2025 | Freestyle Libre |
| Amgen INC. | $602.98 | 2019-2025 | Tepezza, Evenity, Repatha |
| Dexcom, INC. | $498.02 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.08 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $303.14 | 2019-2024 | |
| Pfizer INC. | $264.30 | 2019-2025 | |
| Lilly USA, LLC | $223.98 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Insulet Corporation | $209.73 | 2019-2024 | Omnipod |
| Antares Pharma, INC. | $98.76 | 2019-2025 | Xyosted |
| Tandem Diabetes Care, INC. | $90.36 | 2019-2020 | |
| Radius Health, INC. | $78.76 | 2019-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $76.33 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.21 | 2019 | |
| Xeris Pharmaceuticals, INC. | $62.70 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Shire North American Group INC | $59.22 | 2019 | |
| Abbvie INC. | $56.24 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $52.73 | 2019-2023 | Seglentis, Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $47.79 | 2023 | |
| Recordati_rare_diseases_inc. | $45.40 | 2023 | Signifor Lar, Isturisa |
| Merck Sharp & Dohme LLC | $43.11 | 2019-2020 | |
| Eisai INC. | $40.98 | 2024-2025 | |
| Corcept Therapeutics | $33.85 | 2020-2025 | Korlym |
| Medtronic Minimed, INC. | $30.45 | 2019-2020 | |
| Valeritas, INC. | $29.89 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $24.46 | 2019 | |
| Intuity Medical INC | $24.36 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Alvogen INC | $22.73 | 2024 | Teriparatide |
| Cequr Corporation | $22.64 | 2023 | Cequr Simplicity |
| Beta Bionics, INC. | $21.61 | 2024 | Ilet Bionic Pancreas |
| Ipsen Biopharmaceuticals, INC | $20.32 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.82 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $14.31 | 2019 | |
| Alfasigma USA, INC. | $13.40 | 2020 | |
| Glaxosmithkline, LLC. | $11.09 | 2019 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonben Svoboda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.